Every biotech is a race between science and the bank balance. You are spending millions a year on research that may take a decade to produce revenue, funded entirely by investors who will only give you more money if you hit the right milestones first. Runway, the number of months until you run out of cash, is therefore the single number that governs almost every decision a biotech makes. Here is how burn and runway actually work, and how good companies manage them.
The basic arithmetic
Your burn rate is how much cash you consume in a period, usually stated monthly. Your runway is your cash divided by your burn: if you have thirty million dollars and burn two million a month, you have fifteen months of runway. That simple number drives everything, because it tells you how long you have to reach the milestone that will let you raise your next round. And that is the real point: a biotech does not just need to survive, it needs to reach a value-inflection point, a data readout or milestone that makes the company worth more, before the money runs out. Runway that ends before your next inflection point is the definition of trouble.
Where the money actually goes
Biotech burn is dominated by a few categories. Clinical trials are usually the largest, and they scale unpredictably with enrollment and duration. Manufacturing, particularly for biologics and advanced therapies, is expensive and often front-loaded, since you must make drug before you can test it. People are a major fixed cost, and headcount decisions are effectively long-term commitments. Research and preclinical work continue alongside clinical programs. And there are the unavoidable costs of being a company, facilities, legal, regulatory, insurance, and for public companies, the substantial cost of being public. The critical feature is that most of this is committed and hard to reverse quickly, which is why cutting burn in a hurry is so painful.
The milestone-to-milestone logic
The discipline that separates well-run biotechs is planning explicitly from one value-inflection point to the next. Before committing capital, good management asks: what is the next milestone that will meaningfully increase this company’s value, what will it cost to get there, how long will it take, and does our cash cover that with margin for the delays that always happen? Financing rounds are sized to reach an inflection point with buffer, not merely to keep the lights on, because raising money without a value-creating milestone in reach means raising again from a position of weakness. The most dangerous position in biotech is having enough money to keep going but not enough to reach anything that would justify more.
How companies extend runway
When cash gets tight, the levers are limited and each has a cost. Prioritizing the pipeline, cutting or pausing programs to focus resources on the one most likely to create value, is often the most effective and the most painful. Reducing headcount cuts a major fixed cost but damages capability and morale, and it is hard to reverse. Renegotiating with vendors and slowing non-critical spending helps at the margin. Non-dilutive funding, including partnerships, grants, and out-licensing a program, can bring cash without selling equity, which is why business development matters so much to cash-strapped companies. And partnering or out-licensing an asset can fund the rest of the pipeline, though it means sharing the upside. Each option trades something away, which is why the choices are hard.
The mistakes that kill companies
The failures are consistent. Optimistic timelines are the root of most of them, since trials almost always take longer than planned and a runway built on best-case assumptions evaporates. Raising too little to reach a real milestone leaves you fundraising from weakness. Scaling headcount ahead of validation builds a burn rate the science has not yet justified. Waiting too long to cut means the eventual cuts are deeper and come from a worse position. And ignoring the financing environment is dangerous, because a market that welcomes your story today may be shut when you need it, which is why raising when you can, rather than when you must, is a durable piece of wisdom.
The bottom line
Runway is not a finance metric; it is the constraint that shapes every strategic decision a biotech makes, from how many programs to run to when to raise. Manage it by planning explicitly from one value-inflection point to the next, sizing rounds to reach real milestones with genuine buffer, building conservative rather than optimistic timelines, and acting early rather than late when the numbers turn. The companies that survive the hard cycles are rarely the ones with the best science alone; they are the ones whose management understood that in biotech, cash discipline is what buys the time for the science to work.
The signals that a biotech is in trouble
It is useful, whether you are running a company, investing in one, or considering a job at one, to recognize the warning signs that a biotech’s cash position is deteriorating, because they are usually visible before the crisis is announced. A short runway relative to the next data readout is the clearest signal: if a company will run out of money before it reaches the milestone that would justify a raise, something has to give, and that something is usually a painful financing, a fire-sale partnership, or cuts. Watch for a company that raises a small amount that does not obviously reach an inflection point, which often indicates it could not raise more on acceptable terms. Watch for pipeline prioritization announcements, which are frequently the polite framing of cost cuts driven by cash pressure. Watch for a shift in language from ambitious expansion to disciplined focus, which often precedes reductions. Watch for senior departures, particularly in finance, which can signal trouble ahead. And watch for out-licensing of a lead asset, which sometimes reflects genuine strategy and sometimes reflects a need for cash that leaves the company with less than it should have kept. None of these individually proves a company is in trouble, and plenty of well-run companies prioritize pipelines or partner assets for excellent reasons. But in combination, and particularly alongside a runway that does not clearly reach a value-creating milestone, they are worth taking seriously. For employees especially, understanding a prospective employer’s runway and whether it reaches a meaningful readout is one of the most useful and least performed pieces of diligence available, and it is the single question most worth asking before joining a private biotech.
The bottom line, restated
In biotech, cash is not a finance topic; it is the clock that everything else runs against. Plan explicitly from one value-inflection point to the next, size financings to reach real milestones with genuine buffer, build timelines that assume delay because delay is the norm, and act early rather than late when the numbers turn against you. The companies that survive the hard cycles are not necessarily those with the best science. They are the ones whose management understood that runway discipline is what buys the science enough time to prove itself.
Raise when you can, not when you must
The single most valuable piece of financing discipline in biotech is to raise money when the market is open and your story is strong, rather than waiting until the balance sheet forces you to. Companies that wait until they need money raise it from a position of weakness, on worse terms, and sometimes cannot raise it at all, because financing windows close without warning and rarely reopen on your schedule. Opportunistic financing feels unnecessary when cash looks adequate, and it is exactly what separates the companies that survive downturns from the ones that do not.
For the investors who fund these companies, browse the BioMed Nexus venture capital directory, and see our related guides on raising a biotech Series A and budgeting a clinical trial, usually the largest line in the burn.
Frequently asked questions
What is runway in biotech?
Runway is the number of months until a company runs out of cash, calculated as cash divided by monthly burn rate. It governs nearly every biotech decision because it determines how long the company has to reach a value-inflection milestone that would let it raise its next round. Runway that ends before the next inflection point means serious trouble.
How do biotechs extend their runway?
The main levers are prioritizing the pipeline by cutting or pausing programs to focus on the most valuable one, reducing headcount (a major fixed cost but damaging to capability), renegotiating with vendors and slowing non-critical spending, pursuing non-dilutive funding through partnerships or grants, and out-licensing an asset to fund the rest of the pipeline.
What are the biggest cash management mistakes in biotech?
Optimistic timelines are the root of most failures, since trials almost always take longer than planned. Others include raising too little to reach a real milestone, scaling headcount ahead of scientific validation, waiting too long to cut costs so the eventual cuts are deeper, and ignoring the financing environment rather than raising when markets are open.
